Oncogenes and tumor suppressor genes in breast cancer: Potential diagnostic and therapeutic applications

Oncologist

Volumn 9, Issue 4, 2004, Pages 361-377

  Osborne, Cynthia ^a   Wilson, Paschal ^a   Tripathy, Debu ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Biological therapy; Breast cancer; Oncogene; Review; Targeted therapy; Tumor suppressor gene

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 7 HYDROXYSTAUROSPORINE; ADVEXIN; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CANERTINIB; CAPECITABINE; CARBOPLATIN; CI 1003; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; LAPATINIB; MONOCLONAL ANTIBODY; NAVELBINE; PELITINIB; PERTUZUMAB; PLATINUM DERIVATIVE; RAPAMYCIN; RO 31 7453; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CARCINOGENESIS; CARDIOMYOPATHY; CLINICAL TRIAL; DERMATITIS; DIARRHEA; DRUG TARGETING; FATIGUE; GENE FUNCTION; GENE THERAPY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; LIVER TOXICITY; NAUSEA; NEUROTOXICITY; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; DISEASE PROGRESSION; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; PROGNOSIS;

EID: 3542995667     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-4-361     Document Type: Review

References (138)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-28.
2. Beckmann MW, Niederacher D, Schnurch HG et al. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997;75:429-439.
3. Lerebours F, Lidereau R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol 2002;44:121-141.
4. Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet 2003;33(suppl):238-244.
5. Waldman FM, DeVries S, Chew KL et al. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst 2000;92:313-320.
6. O'Connell P, Pekkel V, Fuqua SA et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703.
7. Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
8. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. The Oncologist 2003;8:5-17.
9. Desai KV, Xiao N, Wang W et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002;99:6967-6972.
10. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-137.
11. Oved S, Yarden Y. Signal transduction: molecular ticket to enter cells. Nature 2002;416:133-136.
12. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
13. van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. Association with comedotype ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245.
14. Ross JS, Fletcher JA, Linette GP et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. The Oncologist 2003;8:307-325.
15. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-1172.
16. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-4289.
17. Clynes RA, Towers TL, Presta LG et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-446.
18. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
19. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
20. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
21. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
22. Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 2002;29(suppl 11):22-28.
23. Pegram M, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251.
24. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889-2895.
25. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
26. O'Shaughnessy J. Gemcitabine and trastuzumab in metastatic breast cancer. Semin Oncol 2003;30(suppl 3):22-26.
27. Robert N, Leyland-Jones B, Asmar L et al. Phase III randomized comparative study of trastuzumab and paclitaxel with and without carboplatinum in patients with HER2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S37.
28. Johnston SR, Head J, Pancholi S et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003;9:524S-532S.
29. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137.
30. Agus DB, Gordon M, Taylor C et al. Clinical activity in a phase I trial of HER-2-targeted rhuMab 2C4 (pertuzumab) in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2003;22:192.
31. Witton CJ, Reeves JR, Going JJ et al. Expression of the HER 1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-297.
32. Sartor CI. Epidermal growth factor family receptors and inhibitors: radiation response modulators. Semin Radiat Oncol 2003;13:22-30.
33. Saltz L, Rubin M, Hochster H et al. Cetuximab plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Am Soc Clin Oncol 2001;20:3a.
34. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
35. Albain K, Elledge R, Gradishar R et al. Open-label, phase II multicenter trial of ZD 1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S33.
36. Robertson JFR, Gutteridge E, Cheung KL et al. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 2003;22:7.
37. Baselga J, Albanell A, Ruiz A et al. Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2003;22:7.
38. Winer E, Cobleigh M, Dickler M et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva™ (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002;76(suppl 1):S115.
39. Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003;4:126-137.
40. Hidalgo M, Rowinski E, Erlichman C et al. CCI-779, a rapamycin analogue and multifaceted inhibitor of signal transduction: a phase I study. Proc Am Soc Clin Oncol 2000;19:187.
41. Chan S, Scheulen ME, Johnson S et al. Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer failing prior anthracycline and/or taxane. Proc Am Soc Clin Oncol 2003;22:193.
42. Johnston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492-2499.
43. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-149.
44. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer Res Treat 1998;52:17-28.
45. Loden M, Stighall M, Nielsen NH et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002;21:4680-4690.
46. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-1575.
47. Dai Y, Grant S. Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 2003;3:362-370.
48. Tan AR, Swain SM. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol 2002;29(suppl 11):77-85.
49. Kouroukis CT, Belch A, Crump M et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:1740-1745.
50. Patel B, El-Rayes BF, Gadgeel SM et al. A phase I study of flavopiridol and docetaxel. Proc Am Soc Clin Oncol 2003;22:233.
51. Nahta R, Iglehart JD, Kempkes B et al. Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between Herceptin and flavopiridol. Cancer Res 2002;62:2267-2271.
52. Trigo Perez JM, Gil M, Miles D et al. A multicenter phase II study of the cell cycle inhibitor Ro 31-7453 in patients with metastatic breast cancer who have failed chemotherapy with an anthmcycline and a taxane. Proc Am Soc Clin Oncol 2003;22:16.
53. Shaw VA, Rini BI, Park JW et al. A phase 2 study of UCN-01 in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2003;22:442.
54. Nalepa G, Wade Harper J. Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat Rev 2003;29(suppl 1):49-57.
55. Albanell J, Baselga J, Guix M et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer. Proc Am Soc Clin Oncol 2003;22:16.
56. Nass SJ, Dickson RB. Defining a role for c-myc in breast tumorigenesis. Breast Cancer Res Treat 1997;44:1-22.
57. Varley JM, Swallow JE, Brammer WJ et al. Alterations to either c-erbB2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987;1:423-430.
58. Carroll JS, Swarbrick A, Musgrove EA et al. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002;62:3126-3131.
59. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823.
60. Takahashi T, Nau MM, Chiba I et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-494.
61. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708.
62. Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991;253:49-53.
63. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238.
64. Li FP. Familial cancer syndromes and clusters. Curr Probl Cancer 1990;14:73-114.
65. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
66. Lane DP, Lu X, Hupp T et al. The role of the p53 protein in the apoptotic response. Philos Trans R Soc Lond B Biol Sci 1994;345:277-280.
67. Zou Z, Gao C, Nagaich AK et al. p53 regulates the expression of the tumor suppressor gene maspin. J Biol Chem 2000;275:6051-6054.
68. Wales MM, Biel MA, el Deiry W et al. p53 activates expression of HIC-1, a new candidate tumor suppressor gene on 17p13.3. Nat Med 1995;1:570-577.
69. Mashimo T, Watabe M, Hirota S et al. The expression of the KM1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci USA 1998;95:11307-11311.
70. Thor AD, Moore DH II, Edgerton SM et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-855.
71. Ioakim-Liossi A, Karakitsos P, Markopoulos C et al. p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas. Cytopathology 2001;12:197-202.
72. Fitzgibbons PL, Page DL, Weaver D et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-978.
73. Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk 2 complex. Nature 1996;382:325-331.
74. Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-1210.
75. Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. Endocrinology 1997;138:1995-2004.
76. Kip1 safeguards against inflammatory injury. Nat Med 1998;4:575-580.
77. Spirin KS, Simpson JF, Takeuchi S et al. p27/Kip1 mutation found in breast cancer. Cancer Res 1996;56:2400-2404.
78. Esposito V, Baldi A, De Luca A et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997;57:3381-3385.
79. Loda M, Cukor B, Tam SW et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234.
80. Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-230.
81. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-225.
82. Fredersdorf S, Bums J, Milne AM et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in some human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-6385.
83. Tan P, Cady B, Wanner M et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinoma. Cancer Res 1997;57:1259-1263.
84. Watts CK, Brady A, Sarcevic B et al. Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995;9:1804-1813.
85. Signoretti S, Di Marcotullio L, Richardson A et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633-641.
86. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-1689.
87. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
88. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995;57:1457-1462.
89. Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14:185-187.
90. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-689.
91. Easton DF, Bishop DT, Ford D et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993;52:678-701.
92. Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Ann Rev Genet 1998;32:95-121.
93. Bienstock RJ, Darden T, Wiseman R et al. Molecular modeling of the amino-terminal zinc ring domain of BRCA1. Cancer Res 1996;56:2539-2545.
94. Scully R, Chen J, Ochs RL et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997;90:425-435.
95. Couch FJ, DeShano ML, Blackwood MA et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New Engl J Med 1997;336:1409-1415.
96. Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B et al. Truncation at conserved terminal regions of BRCAI protein is associated with highly proliferating hereditary breast cancers. Cancer Res 1996;56:3216-3219.
97. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-1510.
98. Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncology 2000;18(21 suppl):107S-112S.
99. Grushko TA, Dignam JJ, Das S et al. MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004;10:499-507.
100. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.
101. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-569.
102. Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-2090.
103. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792.
104. Thorlacius S, Sigurdsson S, Bjamadottir H et al. Study of a single BRCA2 mutation with a high carrier frequency in a small population. Am J Hum Genet 1997;60:1079-1084.
105. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60:313-319.
106. Hedenfalk I, Duggan D, Chen Y et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-548.
107. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
108. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997;277:997-1003.
109. Kerangueven F, Essioux L, Dib A et al. Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene 1995;10:1023-1026.
110. Mills GB, Lu Y, Fang X et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001;28(suppl 16):125-141.
111. Nelen MR, van Staveren WC, Peeters EA et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-1387.
112. Bell DW, Varley JM, Szydlo TE et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-2531.
113. Vahteristo P, Bartkova J, Eerola H et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002;71:432-438.
114. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-168.
115. Khanna KK. Cancer risk and the ATM gene: a continuing debate. J Natl Cancer Inst 2000;92:795-802.
116. Lee WH, Bookstein R, Hong F et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987;235:1394-1399.
117. Andersen TI, Gaustad A, Ottestad L et al. Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. Genes Chromosomes Cancer 1992;4:113-121.
118. Obermiller PS, Tait DL, Holt JT. Gene therapy for carcinoma of the breast: therapeutic genetic correction strategies. Breast Cancer Res 2000;2:28-31.
119. Swisher SG, Roth JA, Nemunaitis J et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763-771.
120. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003;4:415-422.
121. Tait DL, Obermiller PS, Hatmaker AR et al. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin Cancer Res 1999;5:1708-1714.
122. Head JF, Elliott RL, Yang DC. Gene targets of antisense therapies in breast cancer. Expert Opin Ther Targets 2002;6:375-385.
123. Hortobagyi GN, Ueno NT, Xia W et al. Cationic liposome-mediated EIA gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001;19:3422-3433.
124. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
125. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-10874.
126. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
127. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003;3:267-275.
128. Rui Z, Jian-Guo J, Yuan-Peng T et al. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 2003;3:433-439.
129. Vamum SM, Covington CC, Woodbury RL et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat 2003;80:87-97.
130. Wilson LL, Vlahou A, Gregory BW et al. A blood test for breast cancer detection. Breast Cancer Treat Res 2002;76(suppl 1):S34.
131. Pusztai L, Ayers M, Simmans FW et al. Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer. Proc Am Soc Clin Oncol 2003;22:1A.
132. Chang JC, Wooten EC, Tsimelzon A et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-369.
133. Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-211.
134. Collins C, Rommens JM, Kowbel D et al. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci USA 1998;95:8703-8708.
135. Albertson DG, Ylstra B, Segraves R et al. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 2000;25:144-146.
136. Setiawan VW, Hankinson SE, Colditz GA et al. HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:213-219.
137. Lymberis SC, Parhar PK, Katsoulakis E et al. Pharmacogenomics and breast cancer. Pharmacogenomics 2004;5:31-55.
138. DeMichele A, Aplenc R, Botbyl J et al. Drug metabolism polymorphisms and outcome in node-positive breast cancer patients: differential impact of glutathione-S-transferase subtypes. Breast Cancer Res Treat 2003;82(suppl 1):S14.